M illion Hearts is a public-private initiative designed to prevent 1 million Americans from suffering from myocardial infarction or stroke within the next 4.5 years. 1 Inaugurated by the Department of Health and Human Services in September 2011, supporting partners soon included private sector institutions such as the Association of Black Cardiologists, the American College of Cardiology (ACC), and the American Heart Association (AHA). The tactics of Million Hearts focus on 2 broad objectives: (1) public health interventions to reduce the risk of cardiovascular disease through dietary reduction of sodium and trans fats and the reduction of smoking in the environment; and (2) clinical interventions, the ABCS, of aspirin use when appropriate, blood pressure (BP) control, cholesterol reduction, and smoking cessation. We believe that this effort can do a great deal to reduce the occurrence of cardiovascular-related deaths in this country. The partnership between the Federal government and professional medical societies as well as private organizations in a joint effort to eliminate cardiovascular disease has great strength in achieving the stated goals and objectives.
The leaders of Million Hearts have been very forthcoming in communicating with their partners about matters such as the performance measures that they are planning to use in the campaign and in asking for input regarding the chosen metrics. As a result, the Clinical Quality Committee of the ACC recently had the opportunity to participate in providing some informal feedback to Million Hearts leadership. In this perspective, we would like to share that feedback because we believe the points made have applicability with respect to the use of performance measures well beyond this single program. What follows, then, are the comments that were sent from the ACC's Clinical Quality Committee to the Million Hearts leadership as part of general public comment on the Million Hearts initiative.
The General Approach
Because we very much want the Million Hearts program to be successful, we wish to ensure that the measures of success are appropriately crafted. Measures that are less than precise could cause the program to be unfairly labeled a failure or could lead to unintended and negative consequences for the people of this country. After careful review of the clinical measures selected for Million Hearts, we have several general observations that we hope will be useful as the program progresses over time.
The ACC has partnered with the AHA over the years to develop performance measures to be used at the provider and practice levels. 2, 3 We recommend that these ACC/AHA performance measures be used whenever the Million Hearts measures are translated to the practitioner or group level. The ACC/AHA and its partner organizations including the AMA-convened Physician Consortium for Performance Improvement (PCPI) have carefully crafted these measures with knowledge that they would be used for accountability purposes at the individual practitioner level. As a result, they are not only evidence based but are designed to minimize the chances of unintended consequences.
We believe there may be potential issues with the proposed BP control and lipid management measures for Million Hearts, and we offer the following comments.
BP Measures
The proposed BP control measure is simply the percentage of hypertensive patients with BPs less than 140/90. This has the potential of putting some patients at risk as noted in an article published in the previous year by members of the ACC/AHA/ PCPI work group who developed the organizations' coronary artery disease and hypertension measures sets. 2 Concerns over using a target BP in this fashion were primarily related to the potential for unintended consequences as physicians begin treating all of their patients to the target. It is clear that not all patients can or should be pushed to these levels. Some patients could develop cardiac or cerebral symptoms with BP levels in this range. This represents significant uncertainty in an important area for a widely implemented national program. We fear that providers could consider 100% to be the goal and would strive to achieve it until advised otherwise. We believe that control of BP needs be personalized to achieve maximal benefit but to avoid adverse consequences.
Another obvious, unintended consequence of the target is an aggravation of disparities as physicians begin to avoid difficult-to-treat hypertensive patients. This would likely have a disproportionate impact on blacks.
The current ACC/AHA hypertension control measure was driven by the above concerns and includes patients in the numerator whose BPs are ≥140/90 but are on ≥2 medications as a way of ensuring that their hypertension is being managed.
Lipid Management Measures
We also see an opportunity to improve the proposed lipid management measure, which is based solely on a target lowdensity lipoprotein (LDL <100 mg/dL) and may be too simplistic on the basis of recent evidence. Statins are not included in the proposed Million Hearts measure, although they have clearly been demonstrated to benefit secondary prevention patients irrespective of baseline LDL, not just patients with LDL ≥100 mg/dL. ACC/AHA/PCPI put an emphasis on the use of statins in the most recent coronary artery disease measures set. The thinking of the work group in doing this was much the same as expressed in the recently published opinion piece by Hayward and Krumholz-that "the model for a simple tailored treatment approach, in which statin treatment intensity is based on a person's overall 5-to 10-year cardiovascular risk regardless of LDL level, was estimated to save about 100 000 more quality-adjusted life years annually while having fewer people on high doses of statins than a treat-totarget approach." 4 In addition, ACC/AHA/PCPI may alter the lipid measure further after the publication of the National Institutes of Health's Adult Treatment Panel IV recommendations later this year. At that point, it may also be worthwhile considering the development of a new measure that would be most closely aligned with the clinical trial evidence, would capture the larger population where benefits greatly exceed risks, be easier to implement, and would promote behaviors that, if followed, would have a far greater impact in terms of both events prevented and lives prolonged at a very high level of value.
Other populations may not be appropriately targeted with this LDL measure. For example, many feel that the evidence is not strong enough to warrant pushing the LDL to low targets in individuals with high LDLs and very high high-density lipoproteins-a situation not uncommon among women in particular.
The ACC/AHA Task Force on Performance Measures (TFPM) could work with Million Hearts to commission one or more studies to compare the effectiveness of these different measures. If, as we suspect, the ACC/AHA/PCPI BP and lipid measures are superior to the Healthcare Evaluation Data and Information Set (HEDIS) measures when used at the physician and practice levels, then we should be able to demonstrate this with actual evidence of impact on clinical outcomes of interest at the population level.
So much of the public discourse on performance measures, especially those related to ambulatory care and the management of chronic disease, is based on personal bias and very little hard evidence. What evidence does exist tends to come from just a few geographic regions, such as Minnesota, where implementation of publicly reported measures has occurred in a very structured, consensus-based fashion. What we really need to know and know fairly quickly is what happens when accountability measures are implemented on a nationwide basis. With this in mind, we need a rapid-cycle approach that would fairly quickly develop actionable information that could in turn be used to make refinements to the measures or scuttle them altogether.
We offer these thoughts collaboratively and constructively, and we look forward to participating in Million Hearts and to assist in making this initiative as successful as possible.
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